Welcome to our dedicated page for Maze Therapeutics news (Ticker: MAZE), a resource for investors and traders seeking the latest updates and insights on Maze Therapeutics stock.
Maze Therapeutics, Inc. (Nasdaq: MAZE) is a clinical-stage biopharmaceutical company that regularly reports news on the progress of its genetics-guided kidney and metabolic disease programs. Company updates often highlight developments in its lead oral small molecule candidates, MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, as well as broader corporate and financial milestones.
News items from Maze commonly cover clinical trial milestones, such as Phase 1 and Phase 2 study results, enrollment updates, and plans for upcoming proof-of-concept trials. For example, the company has issued press releases on first-in-human data for MZE782 in healthy volunteers, describing safety, pharmacokinetics, and pharmacodynamic markers like urinary amino acid excretion and changes in estimated glomerular filtration rate. It has also provided regular updates on the Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease.
Investors and followers of MAZE can also expect financial results announcements, including quarterly earnings press releases furnished on Form 8-K, which summarize research and development spending, cash position, and license revenue. In addition, Maze issues news about financing transactions, such as its oversubscribed private placement of common stock and pre-funded warrants, along with related registration statements for resale of those securities.
Maze’s news flow also includes corporate governance and leadership updates, such as the appointment of a new chief financial officer and the selection of a new chairman of the board, as well as participation in healthcare and investor conferences where management presents the company’s strategy and pipeline. Conference-related releases typically provide webcast details for investors.
This news page aggregates these disclosures so readers can follow Maze’s clinical progress, financing activities, and corporate developments in one place. For investors and observers tracking MAZE, the feed offers a structured view into how the company’s genetics-based approach and lead programs are evolving over time.
Maze Therapeutics (Nasdaq: MAZE) announced that CEO Jason Coloma, Ph.D., will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Feb. 11, 2026 at 3:00 p.m. ET. A live webcast will be available in the Investors section of the Maze Therapeutics website and archived for 60 days.
Maze Therapeutics (Nasdaq: MAZE) announced that CEO Jason Coloma, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.
A live webcast will be available in the Investors section of Maze Therapeutics' website at www.mazetx.com, and the presentation will be archived for 30 days following the event.
Maze Therapeutics (Nasdaq: MAZE) reported Q3 2025 results and pipeline updates on November 6, 2025. The company ended Q3 with $383.9 million in cash, cash equivalents and marketable securities and says this funding provides a runway into 2028. Maze reported positive first-in-human Phase 1 data for MZE782 showing dose-dependent increases in 24-hour urinary phenylalanine and glutamine, tolerability across doses, and an initial dose-dependent eGFR dip; two Phase 2 proof-of-concept trials in PKU and CKD are planned for 2026. Enrollment continues in the Phase 2 HORIZON trial of MZE829 with topline data for initial patients expected by the end of Q1 2026. Q3 YTD financials show higher R&D and G&A expense and a net loss of $96.6 million for the nine months ended September 30, 2025.
Maze Therapeutics (Nasdaq: MAZE) will present seven research abstracts at ASN Kidney Week (Nov 6-9, 2025) in Houston. Presentations include additional pharmacokinetic data from the Phase 1 study of MZE782 and preclinical evidence supporting SLC6A19 inhibition to slow chronic kidney disease (CKD) progression.
The company will also present preclinical and translational data for MZE829, an oral small molecule in Phase 2 for APOL1-mediated kidney disease (AMKD), a CKD subset estimated to affect >1,000,000 people in the U.S. Presentation titles and times span Nov 6–8 and cover APOL1 genetics, functional mapping, SLC6A19 loss-of-function evidence, and MZE782 safety, tolerability, PK, and pharmacodynamic proof-of-mechanism.
Maze Therapeutics (Nasdaq: MAZE) said company management will participate in four investor conferences in November–December 2025: a Guggenheim fireside chat on Nov 11, 2025 at 9:30 a.m. ET, a TD Cowen fireside chat on Nov 13, 2025 at 2:00 p.m. ET, a Jefferies presentation in London on Nov 20, 2025 at 12:00 p.m. GMT / 7:00 a.m. ET, and an Evercore presentation on Dec 3, 2025 at 10:25 a.m. ET.
Live webcasts will be available in the Investors section of the company website and will be archived for 60 days after each presentation.
Maze Therapeutics (NASDAQ: MAZE) appointed Hervé Hoppenot as Chairman of the Board, effective Oct 6, 2025, succeeding Charles Homcy, who remains on the board.
Key corporate items highlighted include an oversubscribed $150 million private placement, encouraging first‑in‑human data for MZE782, and planned 2026 clinical milestones: initiating Phase 2 trials for MZE782 in PKU and CKD and an initial topline Phase 2 readout for MZE829 targeting APOL1‑mediated kidney disease. Hoppenot brings three decades of industry leadership and cited experience growing Incyte from $350M to $4B in revenue as CEO.
Maze Therapeutics (NASDAQ:MAZE) has secured an oversubscribed $150.0 million private placement through the sale of common stock and pre-funded warrants. The company is offering 4,000,002 shares at $16.25 per share and 5,231,090 pre-funded warrants at $16.249 each, with the price representing a premium to the last closing price.
The financing includes participation from notable investors such as Frazier Life Sciences, Deep Track Capital, and Janus Henderson Investors. The proceeds will fund the development of MZE829 for APOL1-mediated kidney disease, initiate Phase 2 trials of MZE782 in phenylketonuria and chronic kidney disease, and advance research programs and the Compass platform.
Maze Therapeutics (NASDAQ:MAZE) announced positive Phase 1 results for MZE782, its oral SLC6A19 inhibitor targeting Phenylketonuria (PKU) and Chronic Kidney Disease (CKD). The trial demonstrated exceptional safety and efficacy metrics, including up to a 42-fold increase in urinary phenylalanine excretion and dose-dependent eGFR changes similar to SGLT2 inhibitors.
The study involved 112 healthy volunteers across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. MZE782 showed favorable pharmacokinetics supporting once or twice-daily dosing, with no serious adverse events reported. The drug achieved a 39-fold increase in urinary Phe excretion with a single 960mg dose and demonstrated significant glutamine excretion increases.
Based on these promising results, Maze plans to advance MZE782 to Phase 2 trials for both PKU and CKD in 2026.
Maze Therapeutics (NASDAQ:MAZE) has appointed Misbah Tahir as Chief Financial Officer, effective immediately. Tahir brings over 20 years of biopharmaceutical industry experience, most recently serving as CFO at IGM Biosciences where he led the company's IPO and raised over $1 billion in financing.
The appointment comes as Maze prepares for key clinical milestones, including MZE782 data in phenylketonuria and chronic kidney disease in Q3 2025 and Phase 2 HORIZON trial data of MZE829 in APOL1-mediated kidney disease in Q1 2026. The company maintains a strong financial position with cash runway extending into 2H 2027.
Maze Therapeutics (NASDAQ:MAZE) reported Q2 2025 financial results and clinical progress updates. The company maintains a strong financial position with $264.5 million in cash, providing runway into H2 2027. Key clinical developments include:
The company's lead programs are advancing with MZE782 Phase 1 trial in healthy volunteers for PKU and CKD, expecting proof of mechanism data in Q3 2025, and MZE829 Phase 2 HORIZON trial for APOL1-mediated kidney disease, with initial data expected in Q1 2026.
Financial results showed R&D expenses of $28.1 million and net loss of $33.7 million for Q2 2025, compared to net income of $139.1 million in Q2 2024, which included $165 million in license revenue from Shionogi and Trace partnerships.